Merck KGaA stock (DE0006599905): Pharma and life science group reports solid Q1 2026 results

Merck KGaA reported first?quarter 2026 earnings with stable revenue and adjusted EBITDA, maintaining its full?year guidance amid ongoing integration of recent acquisitions.

Merck KGaA has reported its first?quarter 2026 results, showing stable revenue and adjusted EBITDA as the German life science and healthcare group continues to integrate recent acquisitions and manage a complex global operating environment. The company confirmed it is on track to meet its full?year 2026 guidance, underscoring resilience in its core pharmaceuticals and life science businesses despite macroeconomic headwinds and regulatory scrutiny in certain markets.

According to Merck’s Q1 2026 earnings release, group revenue came in at roughly 6.5 billion euros, broadly in line with the prior?year quarter when adjusted for currency and portfolio effects, while adjusted EBITDA remained within the expected range. The group highlighted continued demand for its oncology and fertility products, as well as steady growth in its life science tools and services segment, which supplies biopharma and academic customers worldwide. The company also reiterated its 2026 outlook for mid?single?digit revenue growth and stable profitability, assuming no major adverse regulatory or geopolitical shocks.

As of 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck KGaA
• Sector/industry: Pharmaceuticals and life science tools
• Headquarters/country: Darmstadt, Germany
• Core markets: North America, Europe, Asia?Pacific
• Key revenue drivers: Oncology, fertility, life science research tools and services
• Home exchange/listing venue: Frankfurt Stock Exchange (ticker: MRK)
• Trading currency: Euro

Merck KGaA: core business model

Merck KGaA operates as a global science and technology company with two main pillars: Healthcare and Life Science. The Healthcare division focuses on prescription medicines in oncology, fertility and other specialty areas, while the Life Science segment provides research tools, reagents, bioprocessing solutions and laboratory equipment to pharmaceutical, biotech and academic customers. This dual?pillar structure allows Merck to benefit from both recurring demand for life science consumables and higher?margin, innovation?driven pharmaceutical products.

The group’s business model emphasizes long?term contracts and recurring revenue streams in life science, where customers often lock into multi?year supply agreements for critical reagents and bioprocessing materials. In healthcare, Merck relies on patent?protected oncology and fertility brands, as well as pipeline development and lifecycle management, to sustain margins. The company also invests heavily in R&D and strategic acquisitions to expand its portfolio and geographic footprint, particularly in high?growth biopharma markets such as the United States and parts of Asia.

Main revenue and product drivers for Merck KGaA

Within the Healthcare division, oncology remains a key growth engine, with products such as Erbitux and other targeted therapies contributing a substantial share of pharmaceutical sales. Fertility treatments, including gonadotropin?based therapies, also support stable revenue, as demand for assisted reproductive technologies remains robust in many developed markets. Merck continues to invest in clinical trials and regulatory submissions to extend indications and launch next?generation compounds, which could underpin future growth if approvals materialize.

The Life Science segment is driven by demand for cell culture media, chromatography resins, single?use bioprocessing equipment and analytical instruments used in drug development and manufacturing. As biopharma companies scale up production of monoclonal antibodies, cell and gene therapies, and mRNA?based products, Merck’s portfolio of bioprocessing solutions becomes increasingly relevant. The company has also expanded its digital and data?analytics offerings, aiming to position itself as a one?stop partner for end?to?end biomanufacturing workflows.

Why Merck KGaA matters for US investors

For US investors, Merck KGaA offers exposure to a diversified European life science and healthcare group with significant operations in North America. The company’s life science tools and bioprocessing solutions are widely used by US biopharma firms and research institutions, making it a structural beneficiary of ongoing investment in drug discovery and advanced therapies. At the same time, its oncology and fertility portfolios compete in global markets where US payers and regulators play a pivotal role.

Merck KGaA’s shares trade on the Frankfurt Stock Exchange in euros, but US investors can access the stock via American depositary receipts or cross?listed vehicles, depending on availability. The group’s performance is influenced by US?centric factors such as FDA decisions, reimbursement trends and biopharma R&D spending, which can create both opportunities and risks for international shareholders. As a result, Merck KGaA can serve as a proxy for broader life science and specialty pharma themes without being tied to a single US?listed name.

Conclusion

Merck KGaA’s first?quarter 2026 results reflect a stable operating performance across its healthcare and life science businesses, with management reaffirming its full?year guidance. The company continues to navigate integration of recent acquisitions, regulatory dynamics and macroeconomic uncertainty, while maintaining a focus on innovation and operational efficiency. For investors, Merck KGaA represents a diversified exposure to global life science and specialty pharma markets, but its performance will depend on successful pipeline execution, pricing and reimbursement outcomes, and the broader biopharma investment cycle. As with any equity, investors should weigh these factors against their own risk tolerance and time horizon.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.